WSJ: Boston Scientific Stent Study Flawed
...Liberte, the FDA asked the company to show that its anticlogging performance in patients was "non-inferior" to the Taxus Express
In 2006, the company said that it met this test. Using a standard probability measure known as the "p-value," it said that there was less than a 5% chance that its finding was wrong. In April 2007, in the Journal of...
